NZ536302A - Cancer treatment regime with temozolomide - Google Patents
Cancer treatment regime with temozolomideInfo
- Publication number
- NZ536302A NZ536302A NZ536302A NZ53630200A NZ536302A NZ 536302 A NZ536302 A NZ 536302A NZ 536302 A NZ536302 A NZ 536302A NZ 53630200 A NZ53630200 A NZ 53630200A NZ 536302 A NZ536302 A NZ 536302A
- Authority
- NZ
- New Zealand
- Prior art keywords
- temozolomide
- period
- day
- administered
- week
- Prior art date
Links
- BPEGJWRSRHCHSN-UHFFFAOYSA-N Temozolomide Chemical compound O=C1N(C)N=NC2=C(C(N)=O)N=CN21 BPEGJWRSRHCHSN-UHFFFAOYSA-N 0.000 title claims abstract description 57
- 229960004964 temozolomide Drugs 0.000 title claims abstract description 57
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 23
- 201000011510 cancer Diseases 0.000 title claims abstract description 17
- 238000000034 method Methods 0.000 claims description 15
- 201000001441 melanoma Diseases 0.000 claims description 5
- 239000000203 mixture Substances 0.000 claims description 4
- 206010018338 Glioma Diseases 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 208000032612 Glial tumor Diseases 0.000 claims 2
- 238000012986 modification Methods 0.000 claims 2
- 230000004048 modification Effects 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000002775 capsule Substances 0.000 description 3
- 208000003174 Brain Neoplasms Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 2
- 206010025323 Lymphomas Diseases 0.000 description 2
- 208000015634 Rectal Neoplasms Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 208000024313 Testicular Neoplasms Diseases 0.000 description 2
- 206010057644 Testis cancer Diseases 0.000 description 2
- 230000003474 anti-emetic effect Effects 0.000 description 2
- 239000002111 antiemetic agent Substances 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 208000005017 glioblastoma Diseases 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 201000005202 lung cancer Diseases 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 201000011614 malignant glioma Diseases 0.000 description 2
- 201000005962 mycosis fungoides Diseases 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 201000003120 testicular cancer Diseases 0.000 description 2
- FELGMEQIXOGIFQ-CYBMUJFWSA-N (3r)-9-methyl-3-[(2-methylimidazol-1-yl)methyl]-2,3-dihydro-1h-carbazol-4-one Chemical compound CC1=NC=CN1C[C@@H]1C(=O)C(C=2C(=CC=CC=2)N2C)=C2CC1 FELGMEQIXOGIFQ-CYBMUJFWSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- DIWRORZWFLOCLC-UHFFFAOYSA-N Lorazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940072698 ativan Drugs 0.000 description 1
- 229940088007 benadryl Drugs 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012059 conventional drug carrier Substances 0.000 description 1
- ZZVUWRFHKOJYTH-UHFFFAOYSA-N diphenhydramine Chemical compound C=1C=CC=CC=1C(OCCN(C)C)C1=CC=CC=C1 ZZVUWRFHKOJYTH-UHFFFAOYSA-N 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 231100000226 haematotoxicity Toxicity 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 1
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940097496 nasal spray Drugs 0.000 description 1
- 229960005343 ondansetron Drugs 0.000 description 1
- 229940078646 other antiemetics in atc Drugs 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 229940080313 sodium starch Drugs 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- -1 transdermal Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28134899A | 1999-03-30 | 1999-03-30 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ536302A true NZ536302A (en) | 2006-05-26 |
Family
ID=23076905
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ536302A NZ536302A (en) | 1999-03-30 | 2000-03-27 | Cancer treatment regime with temozolomide |
Country Status (18)
| Country | Link |
|---|---|
| EP (1) | EP1165071B1 (enExample) |
| JP (2) | JP2002540148A (enExample) |
| CN (2) | CN102160864A (enExample) |
| AR (1) | AR023185A1 (enExample) |
| AT (1) | ATE310515T1 (enExample) |
| AU (1) | AU780892B2 (enExample) |
| BR (1) | BR0009380A (enExample) |
| CA (1) | CA2368614C (enExample) |
| DE (1) | DE60024243T2 (enExample) |
| DK (1) | DK1165071T3 (enExample) |
| ES (1) | ES2251987T3 (enExample) |
| HK (1) | HK1044111B (enExample) |
| HU (1) | HUP0200805A3 (enExample) |
| NO (1) | NO330651B1 (enExample) |
| NZ (1) | NZ536302A (enExample) |
| TW (1) | TWI276434B (enExample) |
| WO (1) | WO2000057867A2 (enExample) |
| ZA (1) | ZA200107736B (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100366249C (zh) | 2002-09-29 | 2008-02-06 | 天津帝士力投资控股集团有限公司 | 一种替莫唑胺控释给药系统 |
| CN1742723A (zh) * | 2004-09-02 | 2006-03-08 | 天津倍方科技发展有限公司 | 含有替莫唑胺－8－羧酸酯的药物组合物以及该类化合物用于制备抗肿瘤药物的用途 |
| CN1299772C (zh) * | 2004-10-14 | 2007-02-14 | 孔庆忠 | 一种抗癌药物组合物 |
| WO2006052976A2 (en) * | 2004-11-09 | 2006-05-18 | Schering Corporation | Improved dosing regimen of temozolomide for treating cancer based on the patient’s mgmt level |
| CN101370497B (zh) * | 2006-01-17 | 2010-11-17 | 雅培制药有限公司 | 包含parp抑制剂和细胞毒性剂的联合产品及用途 |
| NZ571693A (en) * | 2006-04-05 | 2011-12-22 | Opko Health Inc | Pharmaceutical formulations: salts of 8-[{ 1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy} -methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one and treatment methods using the same |
| AR061618A1 (es) * | 2006-06-26 | 2008-09-10 | Schering Corp | Formas de dosificacion unitaria de temozolomida |
| WO2008022535A1 (fr) * | 2006-08-09 | 2008-02-28 | Tian Jin Tasly Group Co., Ltd. | Composition pharmaceutique pour traiter le gliome du cerveau, son procédé et sa préparation pharmaceutique |
| EP2066672B1 (en) * | 2006-09-29 | 2015-06-24 | Cipla Limited | An improved process for the preparation of temozolomide and analogs |
| JP6112512B2 (ja) * | 2010-12-01 | 2017-04-12 | レクシ ファーマ インコーポレイテッド | 難治性癌を治療するための方法 |
| CN102526038B (zh) * | 2011-01-12 | 2013-09-11 | 北京人福军威医药技术开发有限公司 | 替莫唑胺的脑靶向药物组合物及其应用 |
| CN107397735B (zh) * | 2017-07-28 | 2020-07-10 | 东曜药业有限公司 | 一种替莫唑胺药物组合物及其制备方法和应用 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT859630E (pt) * | 1995-10-04 | 2003-02-28 | Schering Corp | Combinacao de temozolomida e alfa-ifn no tratamento de cancro avancado |
| CA2184546A1 (en) * | 1996-07-31 | 1998-02-01 | Margaret H. Dugan | Method for treating pediatric high grade astrocytoma including brain stem glioma |
| CA2184545A1 (en) * | 1996-07-31 | 1998-02-01 | Pascale Reidenberg | Cancer treatment with temozolomide |
-
2000
- 2000-03-27 NZ NZ536302A patent/NZ536302A/en unknown
- 2000-03-27 ES ES00918435T patent/ES2251987T3/es not_active Expired - Lifetime
- 2000-03-27 JP JP2000607618A patent/JP2002540148A/ja active Pending
- 2000-03-27 AU AU39244/00A patent/AU780892B2/en not_active Ceased
- 2000-03-27 AR ARP000101370A patent/AR023185A1/es unknown
- 2000-03-27 HU HU0200805A patent/HUP0200805A3/hu unknown
- 2000-03-27 AT AT00918435T patent/ATE310515T1/de active
- 2000-03-27 DE DE60024243T patent/DE60024243T2/de not_active Expired - Lifetime
- 2000-03-27 TW TW089105564A patent/TWI276434B/zh not_active IP Right Cessation
- 2000-03-27 EP EP00918435A patent/EP1165071B1/en not_active Expired - Lifetime
- 2000-03-27 BR BR0009380-7A patent/BR0009380A/pt not_active Application Discontinuation
- 2000-03-27 DK DK00918435T patent/DK1165071T3/da active
- 2000-03-27 CA CA002368614A patent/CA2368614C/en not_active Expired - Fee Related
- 2000-03-27 WO PCT/US2000/008079 patent/WO2000057867A2/en not_active Ceased
- 2000-03-27 CN CN2011100359769A patent/CN102160864A/zh active Pending
- 2000-03-27 CN CN00805865A patent/CN1345240A/zh active Pending
- 2000-03-27 HK HK02103318.7A patent/HK1044111B/en not_active IP Right Cessation
-
2001
- 2001-09-19 ZA ZA200107736A patent/ZA200107736B/xx unknown
- 2001-09-28 NO NO20014725A patent/NO330651B1/no not_active IP Right Cessation
-
2007
- 2007-03-20 JP JP2007073722A patent/JP2007169297A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ATE310515T1 (de) | 2005-12-15 |
| AU3924400A (en) | 2000-10-16 |
| JP2002540148A (ja) | 2002-11-26 |
| WO2000057867A2 (en) | 2000-10-05 |
| CN102160864A (zh) | 2011-08-24 |
| HUP0200805A2 (hu) | 2002-07-29 |
| DE60024243T2 (de) | 2006-08-17 |
| AR023185A1 (es) | 2002-09-04 |
| CA2368614A1 (en) | 2000-10-05 |
| AU780892B2 (en) | 2005-04-21 |
| CA2368614C (en) | 2008-07-22 |
| HK1044111A1 (en) | 2002-10-11 |
| ZA200107736B (en) | 2003-02-26 |
| EP1165071A2 (en) | 2002-01-02 |
| DE60024243D1 (de) | 2005-12-29 |
| NO20014725L (no) | 2001-11-13 |
| NO330651B1 (no) | 2011-05-30 |
| NO20014725D0 (no) | 2001-09-28 |
| BR0009380A (pt) | 2001-12-26 |
| EP1165071B1 (en) | 2005-11-23 |
| HUP0200805A3 (en) | 2004-07-28 |
| WO2000057867A3 (en) | 2001-04-19 |
| ES2251987T3 (es) | 2006-05-16 |
| TWI276434B (en) | 2007-03-21 |
| CN1345240A (zh) | 2002-04-17 |
| JP2007169297A (ja) | 2007-07-05 |
| HK1044111B (en) | 2006-02-24 |
| DK1165071T3 (da) | 2006-02-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5939098A (en) | Cancer treatment with temozolomide | |
| JP2007169297A (ja) | テモゾロミドを用いる改善された癌処置 | |
| CN100411628C (zh) | 空间位阻的铂配位化合物与非铂抗癌剂的组合及其应用 | |
| JP2016520622A5 (enExample) | ||
| US6346524B1 (en) | Cancer treatment with temozolomide | |
| US7705049B2 (en) | Methods for treating non-melanoma cancers with PABA | |
| US6391911B1 (en) | Coadministration of lucanthone and radiation for treatment of cancer | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| Šterba et al. | High-dose methotrexate and/or leucovorin rescue for the treatment of children with lymphoblastic malignancies: do we really know why, when and how? | |
| US5824346A (en) | Combination therapy for advanced cancer | |
| Ackermann et al. | Topotecan in cervical cancer | |
| CA2184545A1 (en) | Cancer treatment with temozolomide | |
| EP1359979B1 (en) | Anti cancer combination of substituted pyrroles and paclitaxel | |
| Tankanow | Docetaxel: a taxoid for the treatment of metastatic breast cancer | |
| JP2003521497A (ja) | 癌のための組み合せ治療 | |
| EP0858341B1 (en) | Combination therapy for advanced cancer comprising temozolomide and cisplatin | |
| JP5590560B2 (ja) | 組合せ抗がん剤 | |
| MXPA01009926A (en) | Improved cancer treatment with temozolomide | |
| Zalupski et al. | Phase II study of pyrazoloacridine in patients with advanced colorectal carcinoma | |
| US5942247A (en) | Method for treating pediatric high grade astrocytoma including brain stem glioma | |
| DeMario et al. | A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days | |
| RU2341260C2 (ru) | Комбинации, включающие производные эпотилона и алкилирующие агенты | |
| CA2184546A1 (en) | Method for treating pediatric high grade astrocytoma including brain stem glioma | |
| CN101835474A (zh) | 用于在狗中治疗淋巴瘤的伊达比星 | |
| EP0550446A1 (en) | Radioprotection by calcium antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |